Nobel Prize-winning technology may enable delivery of up to 12x the standard doxorubicin dose

AACI publishes report on staff retention at clinical trials offices

The AACI CTO Staff Retention Task Force published a report that highlights key data from two surveys distributed to cancer center directors in March 2022 and again in March 2023.

September 15, 2023

Vol.49 No.34

In Brief

KU establishes four-state Heartland Consortium as part of All of Us Research Program

The University of Kansas Medical Center is establishing a Midwest consortium as part of the National Institutes of Health’s All of Us Research Program. KU Medical Center and its partners will receive $6.3 million in initial funding, with the potential to renew the award every year for four years.

September 15, 2023

Vol.49 No.34

In Brief

Navid Hafez named director of precision medicine and thoracic oncology at the Angeles Clinic

Hematologist-oncologist Navid Hafez was named director of precision medicine and thoracic oncology at the Angeles Clinic and Research Institute, an affiliate of Cedars-Sinai Cancer.

September 15, 2023

Vol.49 No.34

In Brief

Jersey Shore University Medical Center to establishes phase I clinical trials unit

Hackensack Meridian Hackensack University Medical Center’s John Theurer Cancer Center established a satellite phase I clinical trial program at Jersey Shore University Medical Center, providing patients access to novel drugs or combinations of drugs for those in need of new options.

September 15, 2023

Vol.49 No.34

Clinical Roundup

Lung-MAP master protocol expands trial access

As compared to conventional, stand-alone clinical trials in advanced non-small cell lung cancer, the biomarker-driven Lung Cancer Master Protocol, or Lung-MAP, has enrolled higher percentages of patients who are older, patients who are from rural or socioeconomically deprived areas, and patients who have Medicaid or no insurance.

September 15, 2023

Vol.49 No.34

In Brief

Exact Sciences Lab and OncoExTra test selected by NCI for ComboMATCH clinical trials

NCI has selected Exact Sciences Corp.’s testing laboratory in Phoenix, AZ to participate in the ComboMATCH clinical trials, an NCI-funded precision medicine initiative. As a ComboMATCH-designated lab, Exact Sciences will use its new OncoExTra test to analyze tumor tissue and paired normal blood samples from patient participants and uncover the specific abnormalities in a patient’s tumor that may be most effective to treat.

September 08, 2023

Vol.49 No.33

Nobel Prize-winning technology may enable delivery of up to 12x the standard doxorubicin dose

YOU MAY BE INTERESTED IN

AACI publishes report on staff retention at clinical trials offices

KU establishes four-state Heartland Consortium as part of All of Us Research Program

Navid Hafez named director of precision medicine and thoracic oncology at the Angeles Clinic

Jersey Shore University Medical Center to establishes phase I clinical trials unit

Lung-MAP master protocol expands trial access

Exact Sciences Lab and OncoExTra test selected by NCI for ComboMATCH clinical trials

Renew today!

Subscriber content

Login